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Abstract
The function of A1- and A2a-adenosine receptors in the control of vascular resistance and in the modulation of light-evoked
neuronal activity was investigated in the isolated perfused cat eye. The A1 agonist CCPA, the A1 antagonist CPT, the A2a agonist
CGS 21680 and the A2 antagonist DMPX were used. The agents were applied intra-arterially at concentrations in the low
nanomolar to micromolar range during rod-selective photic stimulation. The flow rate of perfusate, reflecting vascular resistance
and the light-evoked optic nerve response (ONR) were recorded. Our results show a vasodilating effect of both A1 and A2
agonists and a vasoconstricting effect of the respective antagonists. The dose-effect relationships are suggestive, however, of an
A2a receptor-mediated mechanism. The amplitude of the ONR-ON component was decreased during application of both
adenosine-agonists. Analysis of the dose–effect relationships and the blockade of the CCPA-induced decrease by CPT suggests
that inhibition is mediated by A1 receptors. However, CGS 21680-mediated inhibition cannot be explained by unspecific binding
at A1 receptors alone and suggests the involvement of inhibitory A2a receptors. © 1999 Elsevier Science Ltd. All rights reserved.
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1. Introduction
The purinergic nucleoside adenosine acts as an extra-
cellular modulator of various CNS functions. Despite
the ubiquity of adenosine, this nucleoside plays a spe-
cific role in the pre- and postsynaptic modulation of
neuronal activity and in the regulation of metabolic
functions, including vasodilation and enhancement of
glycogenolysis (for review see Williams, 1989). Different
membrane receptors mediate these effects. Four recep-
tors–subtypes have been identified and cloned so far
(Meyerhof, Mu¨ller-Brechlin & Richter, 1991; Zhou, Li,
Olah, Johnson, Stiles & Civelli, 1992; Tucker & Linden,
1993): A1, A2a, A2b, and A3. The A1- and A2-recep-
tors were biochemically and pharmacologically charac-
terized (Reddington & Lee, 1991) by their inhibition
and stimulation, respectively, of adenylate cyclase ac-
tivity, as well as by agonist and antagonist relative
potency. Furthermore, the A2 receptors are divided in
low (A2b) and high affinity (A2a) subclasses.
Recent evidence suggests important functions for
adenosine in the retina (Blazynski & Perez, 1991). Pre-
vious results have shown inhibitory effects of adenosine
on light-evoked neuronal activity of the cat optic nerve
(Blazynski, Cohen, Fru¨h & Niemeyer, 1989; Niemeyer
& Frueh, 1989). The adenosine–receptor subtypes re-
sponsible for this modulation of retinal information
processing are as yet unknown.
The purpose of this study was to investigate the role
of the A1 and A2 adenosine receptors in the perfused
cat eye. We used two specific adenosine receptors ago-
nists (Table 1): the A1 agonist CCPA, and the A2a
agonist CGS 21680C. Two antagonists were also used
(Table 2): the A1 antagonist CPT, and the A2 antago-
nist DMPX. These agents have the advantage of suffi-
cient water solubility for physiological studies, which is
a prerequisite in the perfused eye with an intact blood-
retina barrier. We describe the effects of these com-
pounds on the flow rate (expressing vascular resistance)
and on the optic nerve response (ONR).
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2-Chloro-N6-cyclopentyladenosineCCPA RBI, Natick, USAA1
CGS 21680CA2a 2-p-(2-Carboxyethyl)phenethylamino-5%-N-ethylcarboxamidoadenosine hydrochloride Ciba Geigy, Summit,
USA
Antagonists
8-Cyclopentyl-1,3-dimethylxanthineCPT RBI, Natick, USAA1
3,7-Dimethyl-1-propargylxanthine RBI, Natick, USAA2 DMPX
2. Materials and methods
The experiments were conducted in accordance with
the resolution on the use of animals in research of the
‘Association for research in vision and ophthalmology’
and, with the regulations of the cantonal veterinary
authority of Zu¨rich. Details on the method have been
published previously (Niemeyer, 1981, 1992; Jurklies,
Kaelin-Lang & Niemeyer, 1996).
2.1. Surgery and perfusion
A total of 32 eyes from 23 female cats, about 1 year
old and weighing 2.8–3.5 kg, were purchased from
Ciba-Geigy, Basel, Switzerland and used in this study.
After premedication with atropine sulfate (0.02–0.04
mg:kg, s.c.), the animals were anesthetised first with an
i.m. injection of ketamine hydrochloride (Ketalar, 10–
20 mg:kg) and then with pentobarbital hydrochloride
i.v. (Nembutal, 9–16 mg:kg; Abbott laboratory,
Chicago, IL). Intubation was done after injection of
gallamine triethiodide i.v. as a bolus and subsequent
continuous infusion (Flaxedil, 5–10 mg:kg). Deep anes-
thesia was maintained by continuous pump driven i.v.
application of pentobarbital. The electrocardiogram,
the transcutaneous oxygen saturation and the expira-
tory CO2 were monitored continuously, and a respira-
tion pump (model 66IA, Harvard Apparatus, South
Natick, USA) was used for artificial ventilation with
oxygen-enriched (30%) room air for up to 12 h. Blood
oxygen saturation above 94% and tidal expiration of
3–4% CO2 were maintained throughout anesthesia.
Rectal temperature (37–39°C) was regulated by a heat-
ing pad. Sodium chloride infusion (0.9%, 10 ml:kg per
h) and occasionally Macrodex 70 i.v. (6%) were used to
maintain fluid- and electrolyte-balance. Fentanyl
(Janssen, Baar, Switzerland, 0.05 mg bolus i.v.) was
applied prior to each surgical procedure to ensure
analgesia. Eyes were enucleated after atropine- and
phenylephrine-induced mydriasis and under anticoagu-
lation (Liquemin, 1000–2000 U, Roche Pharma, Basel,
Switzerland bolus i.v.). A corresponding amount of
protamine hydrochloride (1000–2000 U, Roche
Pharma) was injected after the enucleation of the first
eye. Animals were sacrificed after enucleation of the
second eye by an overdose of Nembutal.
After cannulation of the ophthalmociliary artery, the
eyes were perfused with oxygenated tissue culture
medium with Earle’s salts (TC 199, Bioconcept:
Amimed, Allschwil, Switzerland), containing also L-glu-
tamine (200 nM), amikacin-sulfate (63.9 mM, Amikin,
Bristol-Meyers Squibb AG, Baar, Switzerland) and
newborn calf serum (30% v:v). The perfusate was
buffered with HEPES (15 mM) and NaHCO3 (26 mM)
to a pH of 7.4 at 37°C and gassed with humidified
oxycarbon (95% O2, 5% CO2) for 25 min to reach a pO2
of 400–450 mmHg.
The flow rate was continuously recorded via an
infrared drop-interval meter with an analog voltage
output. Constant hydrostatic pressure drove the perfu-
sion system, such that changes in flow rate reflected
changes in the total vascular resistance of the eye.
2.2. Stimulation and recording
The source for the light stimuli was a 150 W xenon
arc lamp providing a maximum of 11.54 log quanta
[scot., 507 nm] degree-2 second-1. The stimuli were
applied in Maxwellian view (Gouras & Hoff, 1970).
Attenuation of the light flashes was performed with
neutral density filters and narrow band chromatic filters
to achieve rod-matched conditions for short and long
wavelength light pulses in full dark adaptation. The
duration of the stimulus was 400 ms, and the interval
between stimuli was 60 s.
Light-evoked compound action potentials of the op-
tic nerve (optic nerve response, ONR) were recorded
with an Ag–AgCl suction electrode at the cut end of
the nerve and with a Ag–AgCl reference electrode on
the surface of the optic nerve, amplified (PARC 113,
EG & G, Mu¨nchen, Germany), band-pass filtered from
0.02–100Hz (Krohn-Hite 3750, Tecton, Bubikon,
Switzerland), fed to a digital oscilloscope (Gould digital
storage oscilloscope 4050, Cleveland, OH) and to a FM
magnetic tape recorder. The ONR was also registered,
at expanded time-scale, on a chart recorder (Gould RS
3400) using the analog outputs of the digital
oscilloscope.
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Table 2
Effects of the four substances on the flow rate and on the ONR-ON at the different concentrations
Effects on the flowRange Effects on the ORNSubstance
Concentration n Trials:eyes Flow changes ONR-ONConcentration n Trials:eyes
changes (%)(mM)(%)(mM)
LowCCPA (A1- 0.04390.004 2:2 0 0.04390.004 2:2 20.7
agonist)
0.6390.4 7:5 2.791.8 0.7390.55 3:2Medium 21.792.9
5.692.96 8:5 8.394.7 8.295.9High 7:4 27.1987
CGS (A2a-agonist) Low 0.0290.016 6:2 2.791.8 0.0290.016 6:2 5.893.1
0.6490.35 5:3 6.892.9 0.6290.32 6:4Medium 25.391.4
2.891 13:7 6.593.5 6.291.3High 14:8 22.591.58
CPT (A1- Low — — — — — —
antagonist)
0.790.52Medium 3:2 1.792.9 0.790.52 3:2 1.1793.51
2.5 2:2 392.8 2High 1:1 30
DMPX (A2- Low — — — — — —
antagonist)
Medium 1 1:1 1 1 1:1 0
12.591.2 6:4 1.991.86 14.6911.5 5:4High 399.24
Data are expressed as mean9S.D.
The filtered ONR signals and the flow signal were
also fed into a computer system for data analysis and
storage. This system consisted of a personal computer
(IBM 486DX66), an A:D converter (LabPC , Na-
tional Instruments, Ennetbaden, Switzerland) and soft-
ware created with the ‘Labview for windows’ graphical
programming language (Kaelin-Lang & Niemeyer,
1995). It allows on-line analysis of the flow rate and of
the amplitude of the ONR components with trend
analysis, as well as off-line analysis and plotting of the
data. Pharmacologically induced changes in the ampli-
tude of three ONR components were analysed and
compared to control: the ONR-ON component (i.e. the
maximal amplitude after light-onset), the plateau, and
the ONR-OFF component (Fig. 4). The configuration
of the OFF-component of the ONR varies between
preparations (Niemeyer, 1981). It is therefore difficult
to quantify the changes in the ONR-OFF component
induced by the various agents. The ONR-ON compo-
nent, in contrast, has a constant configuration at a
given stimulus intensity. We have therefore only
quantified the changes in the amplitude of the ONR-
ON component.
The ERG b-wave and the standing potential of the
eye were also recorded to continuously monitor the
functional state of the isolated eye, following a routine
procedure. Drug-induced changes in these not entirely
neuronal potentials are not included here for the sake
of clarity (Kaelin-Lang, Jurklies & Niemeyer, 1995).
At the beginning of the electrophysiological record-
ings, immediately after onset of perfusion, 20 ms red
light pulses were applied every min for at least 60 min
to monitor dark adaptation and in vitro steady-state
responsiveness. If the ERG b-wave failed to reach a
steady-state amplitude of 700–800 mV, indicating inad-
equate perfusion, the eye was not used for pharmaco-
logical trials.
2.3. Pharmacological trials
The following agents were used (Table 1): 2-chloro-
N6-cyclopentyladenosine (CCPA, A1 agonist), 3,7-
dimethyl-1-propargylxanthine (DMPX, A2 antagonist),
8-cyclopentyl-1,3-dimethylxanthine (CPT, A1 antago-
nist) (all from RBI, Natick, USA), 2-p-(2-car-
Fig. 1. Time course of changes in normalized flow rate induced by the
A1 agonist CCPA and the A2a agonist CGS at low concentrations
(40 nM) in a typical experiment. The horizontal lines represent the
injection time for CCPA (thin line) and CGS (thick line). CGS causes
a clear increase in flow rate, indicating a vasodilation, whereas CCPA
shows no clear effect.
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Fig. 2. Flow changes in relation to the concentration of the agonists and antagonists. Each column represents the mean of the effects, and the
corresponding numbers of trials:eyes are listed in Table 2. CGS causes a vasodilation at lower concentrations than CCPA. At higher
concentrations, no differences are seen between both agonists. Both antagonists caused a dose-related vasoconstriction at similar concentrations.
The concentration ranges in this and subsequent figures are as follows: low: 1–100 nM, medium 0.1–1.1 mM, high: 2–50 mM. Significant
differences were seen between: (1) CCPA at medium concentration and CCPA at high concentration (P0.0012), also there were significant
differences between CCPA at medium concentration and CGS at medium (P0.028) as well as CGS at high concentrations (P0.012),
suggesting involvement of different adenosine receptors; (2) significant differences were seen between CGS at low concentration and CGS at higher
concentrations (P0.015–0.03), as well as between CGS at low concentration and CCPA at high concentrations (P0.0016); (3) significant
differences were seen between CPT at medium concentration and the agonists at medium and high concentrations (P0.0002–0.045); (4)
significant differences were seen between DMPX at high concentration and all the agonists groups (PB0.0001 to P0.013).
boxyethyl)phenethylamino-5%-N-ethylcarboxamido ade-
nosine hydrochloride, CGS 21680C, briefly referred to
as CGS, A2a agonist (generously provided by Ciba
Geigy, Summit, NJ). The compounds were dissolved in
Ringer’s solution. The antagonist CPT was dissolved
under sonication. All substances were injected intra-ar-
terially by pump driven syringes (Perfusor secura B.
Braun, Bender & Hobein, Zu¨rich, Switzerland, or Har-
vard Apparatus 22). The effective intra-arterial concen-
tration depended on the relationship between the
injection rate and the perfusion rate. Every compound
was injected at least once in isolation during a first trial
in a new preparation. In subsequent trials agonists were
injected before, during and after application of antago-
nists. The following agonist–antagonist combinations
were used: CCPA and CPT, CGS and DMPX, CGS
and CPT.
The signals and flow rate data recorded in the 5 min
preceding the application of agents were used as control
values. The mean of these data was set to 100%. The
injection rate of the agents was always low enough to
avoid noticeable diluting effects of the nutrients in the
perfusate. Control series with injection of Ringer’s solu-
tion alone at the same rate did not show any significant
effects. After having reached a steady-state in the re-
sponse, application of the drug was stopped, and
washout was then allowed for 30–60 min. Trials with-
out clear recovery during the washout period were
Fig. 3. Time course of changes in normalized ONR-ON component
amplitude induced by both agonists, CGS and CCPA, at low concen-
trations (40 nM) in two typical trials. The horizontal lines represent
the injection time for CCPA (thin line) and CGS (thick line). Both
substances caused a decrease in the ONR-ON component amplitude.
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Fig. 4. Effects of the four substances (A1-agonist CCPA, A2a-agonist
CGS, A1-antagonist CPT, A2-antagonist DMPX) on the optic nerve
response (ONR). Each trace is the mean of three signals, registered
during the control period (thin line) and during application of the
active substance (thick line). The light pulse (400 ms) is shown on the
bottom. The vertical lines represent a calibration bar of 50 mV.
observable effects in three trials (summarized as mean
values in Table 2). CCPA never caused a vasoconstric-
tion. The maximal increase in flow rate of the perfusate
was 15%. The A2a adenosine agonist CGS (2 nM–5
mM) showed a similar reversible vasodilation in 23 of a
total of 24 trials. In one trial CGS did not show any
effects. The maximal increase in flow rate was 14%.
Like CCPA, it never caused a vasoconstriction. The
CGS effect was reversible.
Comparison in the dose–effects relationship between
both substances reveals that CGS acted already at
concentration below 100 nM (flow increase of 2.7%),
whereas the A1 agonist CCPA induced no observable
response (Fig. 1). In the ‘medium’ range, CGS caused
an increase of 6.8% and CCPA of 2.7% (Table 2). The
difference between them was statistically significant
(Fig. 2). At ‘higher’ micromolar concentrations, the
effects of both substances were similar: CGS induced an
increase of 6.5% and CCPA of 8.3% (Table 2 and Fig.
2).
The A1-antagonist CPT (0.1–3 mM) induced a de-
crease in flow rate, indicating vasoconstriction, in three
out of five trials, and the A2-antagonist DMPX (1–30
mM) had similar effects in five of a total of seven trials
(Table 2). These effects were dose-related (Fig. 2). The
maximal observed flow decrease was 5% for both sub-
stances. These flow-decreasing effects at medium and
high concentrations of antagonists were significantly
different from the flow-increasing effects of agonists
(Fig. 2, for statistical details see legend of Fig. 2).
In few experiments (n3), CGS was injected during
injection of CPT. The CGS-induced vasodilation was
modified only at higher CPT concentrations: 100 nM
and 1 mM CPT did not change the absolute observed
vasodilation, and a CPT concentration of 3 mM de-
creased the maximal reached vasodilation (1%). The
vasodilating effect of CGS (2 and 3.2 mM) was also
modified by DMPX (21 and 30 mM) in two trials. The
maximal observed flow increase was decreased by 2%.
An additional effect of DMPX was a shortening of the
recovery time of the CGS actions (data not shown).
3.2. Effects of adenosinergic agents on the optic ner6e
action potential (ONR)
The A1 agonist CCPA induced a decrease in the
amplitude of the ONR-ON component in dark adapted
perfused cat eyes (Figs. 3 and 4) in eight trials out of 12
(40 nM–20 mM). The maximal effect was a decrease by
50%. At low nanomolar concentration, CCPA induced
a decrease by 20% (summarized as mean values inTable
2, Fig. 5). In the ‘medium’ concentration range, the
decrease in the amplitude of the ONR-ON component
was similar: 21.7%. At higher concentrations, however,
CCPA caused a decrease in three trials and an increase
in four. The maximal increase by 300% was observed
excluded from further evaluation. For statistical evalua-
tion, the data were divided in three concentrations
ranges: ‘low’, for intra-arterial concentrations between
1 nM and 0.1 mM, ‘medium’ for concentrations be-
tween 0.1 and 1.1 mM, and ‘high’ for concentrations
between 2 and 50 mM. Due to the limited number of
authorized experiments with cats, the number of trials
for the attempted dose-response had to be kept at a
minimum. Difference between groups with n]3 were
analyzed with ANOVA using a ‘StatView’-Software.
Post-hoc testing was done with Fisher PLSD. Signifi-
cance level was set to PB0.05.
3. Results
3.1. Effects of adenosinergic agents on the flow rate of
perfusate
Adenosine agonists, acting at both A1 and A2a
receptors, caused an increase in the flow rate of the
perfusate corresponding to a vasodilation (Table 2).
The A1 adenosine agonist CCPA induced a vasodila-
tion in 14 of a total of 17 trials (40 nM–10 mM) and no
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Fig. 5. Changes in normalized ONR-ON component amplitude in relation to the concentration of the agonists and of the antagonists (each
column represents the mean of the effects). CCPA induced a decrease at low and medium concentrations and an increase with some variability
at higher concentration. CGS induced also variable effects, but consistent and reversible decreases were observed already at low-nanomolar
concentrations. CPT induced an increase in ONR-ON component amplitude whereas DMPX induced small and inconsistant effects. Significant
differences were seen only between CCPA at high concentrations and: (1) CGS at medium concentrations (P0.018); as well as (2) CGS at high
concentrations. (P0.008).
once at the highest applied concentration of 20 mM.
The mean effect was an increase by 27.1% (Fig. 5).
This unusual variabilty of effects (large S.D. in Table
2) was observed using CCPA at high concentrations.
With the A2a agonist CGS, 26 trials with concentra-
tions from 2 nM–50 mM were evaluated. Twenty out
of a total of 26 trials showed a decrease in the ONR-
ON component (Figs. 3 and 4; mean values in Table
2). The maximal effect was a decrease by 50%. This
inhibitory effect was long-lasting and revealed a slow
and sometimes incomplete recovery (Fig. 3).
In the ‘low’ concentration range, CGS induced a
decrease by 5.8% (mean, Fig. 5). The variability was
however high, and in two trials CGS increased the
ONR-ON component amplitude. In the ‘medium’ con-
centration range, CGS induced a decrease by 25.3%
(mean, Table 2). An increase in ONR-ON amplitude
was never seen. At higher concentrations, an ONR-
ON decrease by 22.5% was observed (Table 2, Fig. 5).
A prominent feature of CGS effects on the ONR-
ON component was a clear tachyphylaxis, as illus-
trated in Fig. 7: the first trial in a given preparation
always induced a more marked decrease than the fol-
lowing, and the recovery time took longer in the first
trial. In contrast to CGS, repeated applications of
CCPA failed to reveal tachyphylaxis in all our trials,
and the recovery time was usually faster compared to
that of CGS.
Despite the enhancing effect of CCPA at higher
micromolar concentrations, no significant differences
were seen between both agonists in the medium and
low concentration range (Fig. 5, see also legend for
statistics): CCPA and CGS caused a similar decrease
in the ONR-ON amplitude at low and at medium
concentrations.
The A1 antagonist CPT enhanced the ONR-ON
component in all four trials (Fig. 5, Table 2). This
effect was reversible. In concentrations between 0.1
and 1 mM, the mean increase was by 1.17%, whereas a
concentration of 2 mM (n1) increased the ONR-ON
by 30% (Table 2, Fig. 5). The A2 antagonist DMPX
(1–30 mM), in contrast, revealed no consistent effect
on the ONR-ON component: we observed no effect in
three, an enhancing effect in one (9%), and a decreas-
ing effect in two (9 and 15%) out of a total of six
trials (1–30 mM). No dose–effects relationship was
observed in this small sample (Fig. 5).
The depressing effects of the A1 agonist CCPA on
the ONR-ON component were completely antagonized
by the simultaneous injection of the A1 antagonist
CPT (Fig. 6B). Moreover, a reversible increase of 17%
was observed (n1).
The depressant effects of the A2a agonist CGS in
micromolar concentrations (2–3.2 mM) was not antag-
onized by CPT (n3). On the other hand, the A2
antagonist DMPX (15–30 mM) antagonized the effects
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of CGS (n2) (Fig. 6A). However, the observed tachy-
phylaxis must be taken into account. As a consequence,
the control trials with CGS alone after the simulta-
neous injection of DMPX and CGS showed smaller
effects than the previous control trial (Fig. 6A).
4. Discussion
The results obtained with agonists and antagonists of
adenosine provide further evidence for a physiological
purinergic tone in the ocular vascular system as well as
in the neuronal circuitry subserving retinal information
processing.
4.1. Vascular effects
Agonists at both adenosine A1 and A2a receptors
caused an increase in flow rate, and both specific antag-
onists exerted the opposite effects. Because the perfu-
sion flow-rate is driven by constant hydrostatic
pressure, the observed changes in flow rate reflect
changes in vascular resistance of the whole isolated eye,
i.e. the choroidal, ciliary and retinal vascular beds.
Adenosine is known to be a potent vasodilator (first
described by Drury & Szent-Gyoergyi, 1929) in the
periphery as well as in the CNS (see Phillis (1989), for
review). Ocular vasodilation in response to adenosine in
the perfused cat eye has been previously described
(Blazynski et al., 1989). Other studies have also demon-
strated a vasodilatory action of adenosine on ocular
blood flow (Portellos, Riva, Cranstoun, Petrig &
Brucker, 1995) and on retinal blood vessels (Gidday &
Park, 1993). Studies in the intact eye in vivo indicate
that vasodilation of the choroid accounts for most of
these effects (Portellos et al., 1995).
Based on the relative potencies of the agonists and
antagonists, it was postulated that the A2 receptors
mediated these effects (Portellos, et al., 1995). The
differences between the effects of CGS and of CCPA at
low concentration (Fig. 2) confirm this hypothesis.
Moreover, since CGS has a very low affinity for A2b
receptors, the observed ocular vasodilation is probably
A2a-receptor mediated. At concentrations above 1 mM,
effects of both substances are similar, indicating that
CCPA in higher concentration is no longer specific for
A1 receptors. These findings are in accordance with
binding- and functional assays (Williams, 1991). The
vasoconstrictive effects of both antagonists used here
are indicative of an adenosinergic vascular tone. The
fact that the A1 antagonist CPT induced a vasocon-
striction at concentrations similar to those of DMPX
does not speak against an A2 mediated vasodilation
since the affinity of both antagonists for A2 receptors is
similar, whereas CPT has a much higher affinity for the
A1 receptors than DMPX (Williams, 1991).
4.2. Effects on the optic ner6e compound action
potential
As in other parts of the CNS, evidence has accumu-
lated for a neuromodulating function of adenosine in
the mammalian retina: a subpopulation of nerve cells
with a high content of adenosine has been identified
immunohistochemically in the retina (Braas, Zarbin &
Snyder, 1987), flicker-light and high potassium concen-
tration have been shown to cause a release of adenosine
metabolites (Perez, Ehninger, Lindstro¨m & Fredholm,
1986; Perez, Arner & Ehninger, 1988; Paes de Car-
valho, Braas, Snyder & Adler, 1990), specific binding
sites have been localized (Blazynski, 1990), and
adenosine has been found to modify intracellular
cAMP levels in the retina (Paes de Carvalho & De
Mello, 1982; Blazynski, Kinscherf, Geary & Ferrendelli,
1986). Moreover, specific A1 binding sites are expressed
mostly in the inner retina, and A1 agonists inhibit
adenylate cyclase (Blazynski, 1987). Previous work
from our laboratory demonstrated an inhibitory action
of adenosine on the ONR as well as on maintained and
Fig. 6. (A) Effects of CGS on the normalized ONR-ON component
amplitude, before, during and after the injection of the A2 antagonist
DMPX (see text). (B) Effects of CCPA on the normalized ONR-ON
component amplitude, before, during and after the injection of the
A1 antagonist CPT. The CCPA-induced depression was completely
antagonized by CPT.
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light-evoked activity of retinal ganglions cells
(Niemeyer & Frueh, 1989; Niemeyer, Frishmann &
Macaluso, 1991).
Our present results show that the A1-agonist CCPA
at nanomolar and low micromolar concentrations
causes a decrease of the amplitude of the ONR-ON
component. The A1 antagonist CPT increases the
ONR-ON component and is able to antagonize the
effects of CCPA. It is therefore probable that A1
receptors in the inner retina are involved in the modula-
tion of light-evoked retinal activity with an inhibitory
action on the ONR-ON component. Moreover, the
observed excitatory effect of CPT alone seems to indi-
cate that the A1 receptors are tonically activated in the
dark adapted cat retina.
Several studies have revealed a co-localization of
adenosine uptake and of neurotransmitters such as
acetylcholine, GABA, and 5-HT in retinal cells. On the
other hand, glutamate and acetycholine agonists en-
hance the release of adenosine (Blazynski & Perez,
1991). It is therefore possible that the observed effects
on the ONR-ON reflect an A1-mediated modulation of
neurotransmitter release involved in the retinal ON-
pathway. In Fig. 4 (top) a depressant effect of CCPA
on the OFF-component of the ONR can be seen.
Effects on the OFF pathway, reflected stronger in the
light-adapted ONR signals have not yet been studied in
detail. Results on effects of exogenous adenosine on cat
retinal ganglion cells of the OFF center X- and Y-type
have been observed previously (Niemeyer et al., 1991).
At higher concentrations, the A1 agonist CCPA in-
duced an increase in the amplitude of the ONR-ON
component in several trials. The mechanism for this
effect is not clear and might reflect unspecific effects
outside of the physiological range. At these concentra-
tions effects at purinergic receptors other than A1 are
likely. The vasodilation may also play a role, since an
increase in blood flow in the perfused cat eye increases
the ONR-ON amplitude (Niemeyer, 1981). However,
other mechanisms are possible. In the rat cerebral
cortex, A1 adenosine-agonists can inhibit the ischemia-
evoked release of excitatory neurotransmitters at low
concentration whereas they enhance the release at
higher concentration (O’Regan, et al., 1992). It has
been suggested that A1-agonists at higher concentration
act at excitatory A2 receptors (O’Regan, Simpson,
Perkins, & Phillis, 1992). The CCPA-induced increase
in flow (Fig. 2A) suggests such a non specific effect of
CCPA at A2-receptors. However, the A2a agonist CGS
mostly failed to induce an increase in the amplitude of
the ONR-ON component. Therefore an A2a-receptor
mediated effect of CCPA seems unlikely.
Consequently, the CCPA-induced increase in the
ONR-ON component could be mediated by other exci-
tatory adenosine receptors or by effects on the
adenosine transporter, concepts that would require fur-
ther investigations.
The specific A2a-adenosine agonist CGS depressed
the ONR-ON component. This effect was apparent at
low-nanomolar concentrations and in spite of the con-
comitant vasodilation, which per se should enhance the
ONR-ON component. This competitive enhancement
of neuronal activity, induced by vasodilation, could
explain the rarely observed increase in ONR-ON ampli-
tude at low concentrations, since the vascular receptors
would probably be reached before the neuronal.
The CGS-induced neuronal inhibition was antago-
nized by DMPX, but not by CPT. These results suggest
that the inhibitory effects of CGS are not mediated by
inhibitory A1 receptors, but possibly by A2 receptors.
In contrast to CPT, DMPX alone failed to induce clear
effects, suggesting that A2 receptors are not tonically
involved in the modulation of the ONR-ON.
A similar depressant action of CGS has also been
observed in cortical neurons (Lin & Phillis 1991). It was
suggested that CGS acts on inhibitory A2 receptors,
and that the inhibitory effect of adenosine is mediated
by A1 as well as by A2 receptors (Lin & Phillis 1991).
A study with CGS in hippocampal slices has sug-
gested that the CGS-induced neuronal inhibition is
mediated by the A1 receptors (Lupica, Wayne, Zah-
niser & Dunwiddie, 1990) The anticonvulsant effects of
CGS in the prepiriform cortex seem also to be mediated
by A1 receptors (Zhang, Franklin & Murray, 1994).
Although in our study it is possible that CGS acts in
part through A1 receptors, our results suggest that the
inhibitory effects of CGS in the retina are not only
mediated by A1 receptors. First, the A1 antagonist
CPT failed to antagonize the effects of CGS, whereas it
antagonizes the effects of the A1 agonist CCPA. Sec-
ond, CGS exhibited inhibitory actions in nanomolar
concentration range at which an A1 effect is unlikely.
Moreover, the permeability of the blood-retina barrier
for CGS is low (communication from Ciba Geigy) such
that the retinal interstitial concentration was probably
Fig. 7. Example of the loss of efficacy with repeated applications of 2
mM CGS. Ordinate: inhibitory effect on ONR-ON amplitude in per
cent. Abscissa: first, second and third consecutive trials performed at
intervals of :60 min. The five trials with CGS were done using both
eyes from the same cat.
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much lower than the intra-arterial concentration in our
trials. However, the affinity of CGS for the A3 recep-
tors is also in the high nanomolar range (Zhou et al.,
1992), and DMPX is an A2 antagonist with low specifi-
city. We therefore cannot exclude that CGS could act
at A3 receptors.
The time-course of the effects of CGS differed from
those of the A1 agonist CCPA. Pharmacokinetic fac-
tors may explain the slow recovery. However, effects of
CGS in cell cultures revealed a desensitization of the
A2a receptors with a rapid reduction in agonist stimu-
lated adenyl cyclase activity, due to a decrease in recep-
tor affinity (Palmer, Gettys, Jacobson & Stiles, 1994).
Such mechanism could explain the observed tachyphy-
laxis (Fig. 7).
In conclusion, our results confirm the vasodilating
function of A2 receptors and the physiological impor-
tance of A1 receptors in the inhibition of light-evoked
neuronal activity in the mammalian eye. However, the
adenosine agonist-induced neuronal inhibition observed
in the optic nerve appears to be a complex process that
can not be explained solely by A1-mediated mecha-
nisms. Other receptors, possibly the A2a receptors,
could play a role.
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